Jeannick Cizeau

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Viventia Biotechnologies Inc., Viventia Bio Inc., Merck Patent Gmbh. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeannick Cizeau. Retrieved from https://idiyas.com/inventor/jeannick-cizeau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 58.8

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Manitoba, CA (2008 - 2014)
Winnipeg, CA (2011 - 2017)

Company Filing History:

7 out of 7

Viventia Biotechnologies Inc.

4. 1 out of 834,570

Other

patents

Years Active: 2008-2017

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9822182 - Anti-EPCAM antibodies and methods of use (2017-11-21),

2. 9109223 - Methods for generating and screening fusion protein libraries and uses thereof (2015-08-18),

3. 8999334 - Antibody conjugates against variant NFKBIB and uses thereof (2015-04-07),

4. 8969540 - Tumor specific antibody (2015-03-03),

5. 8946390 - Cancer-associated antigen (2015-02-03),

6. 8716234 - Cytotoxins comprising modified bouganin toxin for the treatment of cancer (2014-05-06),

7. 8697075 - Cancer specific antibody and cell surface proteins (2014-04-15),

8. 8426561 - Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof (2013-04-23),

9. 8389286 - Cancer-associated antigen (2013-03-05),

10. 8383117 - CD44E tumor specific antibody (2013-02-26),

11. 8318472 - Optimized nucleic acid sequences for the expression of VB4-845 (2012-11-27),

12. 8273550 - Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof (2012-09-25),

13. 8263744 - Binding proteins that bind to EpCAM linked to an effector molecule (2012-09-11),

14. 8084576 - Cancer associated glucose transporter 8 variant (2011-12-27),

15. 7956162 - Cancer-associated antigen (2011-06-07),

Title: The Innovative Contributions of Jeannick Cizeau

Introduction

Jeannick Cizeau is an accomplished inventor based in Winnipeg, Canada, known for his significant contributions to the field of biomedicine. With a remarkable portfolio of 17 patents, Cizeau has demonstrated a continuous commitment to innovation and improving medical treatments through cutting-edge technologies.

Latest Patents

One of Cizeau's latest patents involves the development of Anti-EPCAM antibodies and methods of use. This groundbreaking work relates to compositions of antibodies and immunoconjugates that are designed to minimize immune responses by potentially lacking T-cell epitopes. The antibodies may take the form of various fragments, including Fab, Fab', F(ab′)2, and many others. Importantly, these antibodies are engineered to bind to the epithelial cell adhesion molecule (EpCAM), allowing for targeted therapeutic applications. In addition, his patents involve the creation of immunoconjugates that incorporate effector molecules, offering promising applications in cancer treatment.

Another notable invention is directed to methods for generating and screening fusion protein libraries, which can comprise immunotoxin libraries. This invention allows for the efficient development of libraries of recombinant cells encoding nucleic acid sequences containing fusion proteins, facilitating the screening process for fusion proteins that are specifically effective against targeted cells, such as those found in cancerous tissues.

Career Highlights

Throughout his career, Cizeau has worked with leading biotechnology firms, including Viventia Biotechnologies Inc. and Viventia Bio Inc. His dedication and expertise in biomedicine have made him a prominent figure in the industry, recognized for advancing treatments in cancer and other critical areas.

Collaborations

Cizeau has had the opportunity to work alongside talented individuals such as Glen MacDonald and Francina C. Chahal. Their collaborative efforts have fostered an environment of innovation, leading to the development of breakthrough technologies that benefit patients and advance the field of biomedical research.

Conclusion

Jeannick Cizeau's contributions to the world of inventions and innovations exemplify the impact that dedicated inventors can have on healthcare. With his extensive patent portfolio and commitment to research, Cizeau continues to be a driving force in the development of advanced medical therapies that aim to improve patient outcomes and revolutionize treatment methodologies.

Profile summary based on public USPTO records.